214 related articles for article (PubMed ID: 27356578)
21. Expression of interleukin 10 in B lymphocytes of different origin.
Finke J; Ternes P; Lange W; Mertelsmann R; Dölken G
Leukemia; 1993 Nov; 7(11):1852-7. PubMed ID: 7694007
[TBL] [Abstract][Full Text] [Related]
22. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
[TBL] [Abstract][Full Text] [Related]
23. The significance of chromosomal findings for the differentiation between lymphoma and lymphoblastoid cell lines.
Hellriegel KP; Diehl V; Krause PH; Meier S; Blankenstein M; Busche W
Haematol Blood Transfus; 1977; 20():307-13. PubMed ID: 580253
[TBL] [Abstract][Full Text] [Related]
24. IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.
Teng Y; Takahashi Y; Yamada M; Kurosu T; Koyama T; Miura O; Miki T
Eur J Cell Biol; 2007 Oct; 86(10):581-9. PubMed ID: 17651861
[TBL] [Abstract][Full Text] [Related]
25. Human B-lymphoid cell lines.
Nilsson K
Hum Cell; 1992 Mar; 5(1):25-41. PubMed ID: 1329931
[TBL] [Abstract][Full Text] [Related]
26. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies against SU-DHL-1 cells stain the neoplastic cells in true histiocytic lymphoma, malignant histiocytosis, and Hodgkin's disease.
Hsu SM; Pescovitz MD; Hsu PL
Blood; 1986 Jul; 68(1):213-9. PubMed ID: 2424524
[TBL] [Abstract][Full Text] [Related]
28. Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Ho YS; Subhendu C; Hsu SM
Cancer Invest; 1987; 5(2):101-7. PubMed ID: 2955857
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. II. receptor-mediated Akt/PKB and ERK1/2 activation and transcription factors expression profile.
Shlapatska LM; Kovalevska LM; Gordiienko IM; Sidorenko SP
Exp Oncol; 2014 Sep; 36(3):162-9. PubMed ID: 25265348
[TBL] [Abstract][Full Text] [Related]
30. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma.
Schneider EM; Torlakovic E; Stühler A; Diehl V; Tesch H; Giebel B
J Pathol; 2004 Dec; 204(5):538-45. PubMed ID: 15538755
[TBL] [Abstract][Full Text] [Related]
31. [Expression of miR-9 in B lymphocytes and B cell lymphomas cell lines and its significance].
Li F; Huang XP; Wang ZQ; Liu FR; Zhou XH; Zhong L; Wu ZQ; Han XQ; Zhu MG; Zhao T
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):249-53. PubMed ID: 21569708
[TBL] [Abstract][Full Text] [Related]
32. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Crespo M; Villamor N; Giné E; Muntañola A; Colomer D; Marafioti T; Jones M; Camós M; Campo E; Montserrat E; Bosch F
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):726-34. PubMed ID: 16467082
[TBL] [Abstract][Full Text] [Related]
33. ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
Guillaume N; Alleaume C; Munfus D; Capiod JC; Touati G; Pautard B; Desablens B; Lefrère JJ; Gouilleux F; Lassoued K; Gouilleux-Gruart V
Haematologica; 2005 Jul; 90(7):899-905. PubMed ID: 15996927
[TBL] [Abstract][Full Text] [Related]
34. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines.
Arguello M; Sgarbanti M; Hernandez E; Mamane Y; Sharma S; Servant M; Lin R; Hiscott J
Oncogene; 2003 Feb; 22(7):964-73. PubMed ID: 12592383
[TBL] [Abstract][Full Text] [Related]
35. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.
Simons-Evelyn M; Bailey-Dell K; Toretsky JA; Ross DD; Fenton R; Kalvakolanu D; Rapoport AP
Blood Cells Mol Dis; 2001; 27(5):825-9. PubMed ID: 11783945
[TBL] [Abstract][Full Text] [Related]
36. Capacity of B-lymphocytic lines of diverse tumor origin to produce and respond to B-cell growth factors: a progression model for B-cell lymphomagenesis.
Gordon J; Aman P; Rosén A; Ernberg I; Ehlin-Henriksson B; Klein G
Int J Cancer; 1985 Feb; 35(2):251-6. PubMed ID: 2982745
[TBL] [Abstract][Full Text] [Related]
37. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells.
Hecht TT; Longo DL; Cossman J; Bolen JB; Hsu SM; Israel M; Fisher RI
J Immunol; 1985 Jun; 134(6):4231-6. PubMed ID: 3157756
[TBL] [Abstract][Full Text] [Related]
38. Classification and biological nature of established human hematopoietic cell lines.
Nilsson K; Pontén J
Int J Cancer; 1975 Feb; 15(2):321-41. PubMed ID: 165156
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease.
Meeker TC; Lay LT; Wroblewski JM; Turturro F; Li Z; Seth P
Clin Cancer Res; 1997 Mar; 3(3):357-64. PubMed ID: 9815692
[TBL] [Abstract][Full Text] [Related]
40. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
